Skip to main content

Advertisement

Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner

Fig. 5

Impaired anticitrullinated protein antibody (ACPA)-induced cytokine release in monocytes isolated from abatacept-treated patients. Upper panel: Levels of interleukin (IL)-6 and IL-1β were measured in the supernatants of monocytes isolated from patients with rheumatoid arthritis (RA) treated with no biologic disease-modifying antirheumatic drug (“−”; only methotrexate) or cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin (CTLA-4-Ig; abatacept) or tumor necrosis factor antibody (TNF-Ab; adalimumab). Monocytes were then stimulated with 100 μg/ml ACPA immune complexes or control immunoglobulin G. *** p < 0.001. Lower panel: Western blots for indoleamine 2,3-dioxygenase (IDO), nuclear factor-κB-inducing kinase (NIK), and action (loading control) expression in monocytes from patients with RA treated with abatacept (n = 4) or adalimumab (n = 4)

Back to article page